Effect of Continuous Glucose Therapy Begun in Infancy on the Long-Term Clinical Course of Patients with Type I Glycogen Storage Disease

1999 ◽  
Vol 29 (2) ◽  
pp. 136-143 ◽  
Author(s):  
Joseph I. Wolfsdorf ◽  
John F. Crigler
2000 ◽  
Vol 67 (7) ◽  
pp. 497-501 ◽  
Author(s):  
Inci Nur Saltik ◽  
Hasan Özen ◽  
Gönenç Ciliv ◽  
Nurten Koçak ◽  
Aysel Yüce ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yi-Chia Chan ◽  
Kai-Min Liu ◽  
Chao-Long Chen ◽  
Aldwin D. Ong ◽  
Chih-Che Lin ◽  
...  

Abstract Background and aims Glycogen storage disease type I (GSD-I) is an autosomal recessive disorder of carbohydrate metabolism, resulting in limited production of glucose and excessive glycogen storage in the liver and kidneys. These patients are characterized by life-threatening hypoglycemia, metabolic derangements, hepatomegaly, chronic kidney disease, and failure to thrive. Liver transplantation (LT) has been performed for poor metabolic control and delayed growth. However, renal outcome was diverse in pediatric GSD patients after LT. The aim of this study was to investigate the long-term outcome of renal function in pediatric GSD-I patients after living donor LT (LDLT), and to identify modifiable variables that potentially permits LT to confer native renal preservation. Methods The study included eight GSD-Ia and one GSD-Ib children with a median age of 9.0 (range 4.2–15.7) years at the time of LT. Using propensity score matching, 20 children with biliary atresia (BA) receiving LT were selected as the control group by matching for age, sex, pre-operative serum creatinine (SCr) and pediatric end-stage liver disease (PELD) score. Renal function was evaluated based on the SCr, estimated glomerular filtration rate (eGFR), microalbuminuria, and morphological changes in the kidneys. Comparability in long-term renal outcome in terms of anatomic and functional parameters will help to identify pre-LT factors of GSD-I that affect renal prognosis. Results The clinical and biochemical characteristics of the GSD and BA groups were similar, including immunosuppressive regimens and duration of follow-up (median 15 years) after LT. Overall, renal function, including eGFR and microalbuminuria was comparable in the GSD-I and BA groups (median eGFR: 111 vs. 123 ml/min/1.73m2, P = 0.268; median urine microalbuminuria to creatinine ratio: 16.0 vs. 7.2 mg/g, P = 0.099, respectively) after LT. However, in the subgroups of the GSD cohort, patients starting cornstarch therapy at an older age (≥ 6-year-old) before transplantation demonstrated a worse renal outcome in terms of eGFR change over years (P < 0.001). In addition, the enlarged kidney in GSD-I returned to within normal range after LT. Conclusions Post-LT renal function was well-preserved in most GSD-I patients. Early initiation of cornstarch therapy before preschool age, followed by LT, achieved a good renal prognosis.


Author(s):  
Andrey N. Surkov ◽  
A. A. Baranov ◽  
L. S. Namazova-Baranova ◽  
A. S. Karulina ◽  
A. S. Potapov ◽  
...  

Treatment of the glycogen storage disease (GSD) type I with uncooked cornstarch (UCS) allows to maintain long-term normoglycemia, however, the efficacy of the treatment declines due to the insufficient compliance of children patients and their parents. There were determined clinical and laboratory features of the course of GSD type I in children on the long-term comprehensive therapy. There was performed a retrospective analysis of case histories data on 19 GSD children, including 8 patients with subtype Ia and 11 cases - with subtype Ib. All children received the treatment with both UCS and hepatoprotectors. It was established that during the treatment liver sizes did not change significantly, the fasting blood glucose concentration increased by 2.8 times to 4.21 mmol/l, lactate content decreased by 1.9 times to 5.1 mmol/L, ALT activity decreased by 2.5 times, AST - by 3.3 times, and GGT - by 1.8 times if compared to the level before the treatment. In children with GSD subtype Ib blood concentrations of triglycerides prior to the treatment were 2 times higher than baseline values andfailed to change on the comprehensive therapy. Blood levels of cholesterol and uric acid after the treatment also were not significantly dependent on the duration of the therapy. The authors suggest that comprehensive course therapy of GSD type I by means of prescription to children UCS in combination with hepatoprotectors contributes to the compensation of carbohydrate metabolism and provides the relief of cytolysis and cholestasis, but disturbances of the purine and lipid metabolism in patients persist.


Sign in / Sign up

Export Citation Format

Share Document